Mazabraud Yann

EVP Yann Mazabraud sold 17,750 shares at $60.99 blended price, reducing stake by 44.0%

Yann Mazabraud (EVP, Head of International) executed 2 separate sales on 2025-04-08 totaling 17,750 shares for $1,082,497.31 at a blended average price of $60.99, reducing his holdings from 40,370 shares to 22,620 shares. This represents a substantial 44.0% reduction in his position. The current stock price of $57.83 is now 5.2% below the transaction price, placing the trade at a slight premium to today's market level. RYTM is a high-growth company with annual revenue growth of +68.1% but is unprofitable, posting a net loss of $43,641,000.00 against quarterly revenue of $33,251,000.00. The timing of this large stake reduction occurs while the stock is -14.1% from its 52-week high of $67.33, though it remains up +15.5% over the past 30 days. No clear pattern emerges from his prior same-ticker history (2 recent sells on 2025-03-14 with outcomes not yet measurable) or his limited cross-ticker track record (2 prior sells with no well-timed execution metrics available). The scale and composition of the sale—two distinct transactions in a single day—warrants monitoring for context regarding portfolio management or liquidity needs.

EVP Yann Mazabraud sold 75,000 shares (65% of holdings) at $51.48 avg for $3.9M at RYTM on 2025-03-14

Yann Mazabraud, EVP and Head of International at Rhythm Pharmaceuticals, executed 2 separate sales totaling 75,000 shares (75.0K shares) for $3,861,272.38 on 2025-03-14, reducing his stake from 115,370 shares to 40,370 shares post-transaction. The sale represents a 65.0% reduction in his direct holdings. The stock is currently trading at $52.29, approximately 1.6% above the blended average sale price of $51.48, and is down 22.3% from its 52-week high of $67.33 and down 7.8% over the trailing 30 days. The company is unprofitable (net income of $-43.6M in the most recent full fiscal year) despite strong annual revenue growth of 68.1%, suggesting the business is in a high-growth but pre-profitability phase. A substantial reduction of holding concentration by an international business leader warrants tracking of future quarterly results and any public commentary on market conditions or strategic priorities.